IMPORTANT UPDATE FOR CYTODYN SPECIAL MEETING OF
Change in Location of the Special Meeting to be
held on July 22, 2020
Meeting Date: July 22, 2020
Meeting Time: 9:30 a.m. (Pacific Time)
Meeting Access: http://www.meetingcenter.io/285700571
VANCOUVER, Washington, July 08, 2020 (GLOBAL NEWSWIRE)—Due to the
emerging public health impact of the coronavirus outbreak
(COVID-19) and to support
the health and well-being of our employees, stockholders, and our
community please note that the CytoDyn Inc. Special Meeting of
Stockholders will be held on July 22, 2020 in virtual format
only. In person attendance at the Special Meeting by stockholders
will not be permitted.
To access the virtual meeting please click the Virtual
Stockholder Meeting link. To login to the virtual meeting, you
have two options: Join as a “Guest” or Join as a “Stockholder.” If
you join as a “Stockholder,” you will be required to have a control
number and password to login to the virtual meeting. The password
for the meeting is CYDY2020.
If you were a stockholder as of the close of business on
June 17, 2020 and have your control number, you may vote
during the Special Meeting by following the instructions available
on the meeting website during the meeting. For registered
stockholders, the control number can be found on your proxy card or
notice, or email you previously received.
If you hold your shares through an intermediary, such as a bank or
broker, you must register in advance to attend the Special Meeting.
To register you must submit proof of your proxy power (legal proxy)
reflecting your CytoDyn Inc. holdings along with your name and
email address to Computershare. Requests for registration must be
labeled as “Legal Proxy” and be received no later than 5:00 p.m.,
Eastern Time, on July 17, 2020. You will receive a confirmation
email from Computershare of your registration.
Requests for registration should be directed to Computershare at
the following address:
Forward the email from your broker, or attach an image of your
legal proxy, to email@example.com
If you do not have your control number, you may attend as a guest
but will not have the option to vote your shares or ask questions
at the virtual meeting.
Stockholders are reminded to vote their shares whether they plan
to attend the virtual meeting or not. Stockholders may vote their
shares in advance of the meeting by one of the methods described in
CytoDyn’s Proxy Statement filed with the SEC on June 22,
Please note that the proxy card included with the proxy
materials previously distributed will not be updated to reflect the
change in location and may continue to be used to vote your shares
in connection with the Special Meeting.
CytoDyn is a late-stage biotechnology company developing innovative
treatments for multiple therapeutic indications based on
leronlimab, a novel humanized monoclonal antibody targeting the
CCR5 receptor. CCR5 appears to play a critical role in the ability
of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears
to be implicated in tumor metastasis and immune-mediated illnesses,
such as GvHD and NASH. CytoDyn has successfully completed a Phase 3
pivotal trial with leronlimab in combination with standard
antiretroviral therapies in HIV-infected treatment-experienced
patients. CytoDyn filed its BLA in April 2020 to seek FDA approval
for leronlimab as a combination therapy for highly treatment
experienced HIV patients, and submitted additional FDA requested
clinical datasets on May 11, 2020. CytoDyn is also conducting
a Phase 3 investigative trial with leronlimab as a once-weekly
monotherapy for HIV-infected patients. CytoDyn plans to
initiate a registration-directed study of leronlimab monotherapy
indication. If successful, it could support a label extension.
Clinical results to date from multiple trials have shown that
leronlimab can significantly reduce viral burden in people infected
with HIV. No drug-related serious site injection reactions reported
in about 800 patients treated with leronlimab and no drug-related
SAEs reported in patients treated with 700 mg dose of leronlimab.
Moreover, a Phase 2b clinical trial demonstrated that leronlimab
monotherapy can prevent viral escape in HIV-infected patients; some patients on
leronlimab monotherapy have remained virally suppressed for more
than five years. CytoDyn is also conducting a Phase 2 trial to
evaluate leronlimab for the prevention of GvHD and a Phase 1b/2
clinical trial with leronlimab in metastatic triple-negative breast
cancer. More information is at www.cytodyn.com.